Biontech Se ADR (BNTX)$92.14
Market Cap: 24.30 BCurrency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for Biontech Se ADR (BNTX).
HEALTHCARE
BIOTECHNOLOGY
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
N/A
ROIC, N/A FCF margin
Growth
N/A
5Y sales (revenue) CAGR
Balance sheet
N/A
Debt/equity, N/A current ratio
Superinvestors
1
Top: Dodge & Cox (0.2%)
Strengths to research
No strong positive screening signals were detected from the checked-in dataset.
Watchouts
- Full metrics are not available yet for this ticker.
Annual data: 0 periods
Quarterly data: 5 periods
Stock snapshot: May 24, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for BNTX.
Grade F
0
/ 100
Peer Comparison
Target stock against 8 market-cap comparable peers.
Heat map: red worst to green best
| BNTX Target | Biontech Se ADR | $24.3B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| RPRX | Royalty Pharma plc | $19.0B | 30.6x | 11.0x | 4.1% | 2.3% | 104.7% | N/A | 5.3x | N/A |
| ALNY | Alnylam Pharmaceuticals | $35.4B | 127.7x | 72.5x | 39.8% | 49.8% | 12.5% | N/A | -3.0x | N/A |
| INCY | Incyte Corp. | $12.0B | 15.2x | 6.3x | 24.9% | 14.0% | 27.5% | N/A | -1.9x | N/A |
| BMRN | BioMarin Pharmaceutical Inc. | $11.9B | 30.1x | 14.6x | 5.7% | 11.6% | 22.5% | N/A | -2.7x | N/A |
| MRNA | Moderna, Inc. | $10.8B | -6.5x | -4.0x | -32.6% | 19.3% | -106.2% | N/A | N/A | N/A |
| REGN | Regeneron Pharmaceuticals | $65.2B | 15.4x | 15.2x | 14.4% | 11.0% | 28.4% | N/A | -0.8x | N/A |
| ROIV | Roivant Sciences Ltd | $8.3B | -55.5x | -9.0x | -6.6% | -19.1% | -9183.5% | N/A | N/A | N/A |
| TECH | Bio-Techne Corp. | $7.9B | 104.8x | 30.1x | 3.8% | 10.5% | 21.0% | 64.8% | -0.8x | N/A |
Financial Charts
No financial data available for BNTX (annual).
1 superinvestors own BNTX
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Dodge & Cox Dodge & Cox | 3,676,791 | $327M | 0.18% | 0.0% |